Equities research analysts forecast that Recro Pharma Inc (NASDAQ:REPH) will report $13.32 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Recro Pharma’s earnings. The highest sales estimate is $13.35 million and the lowest is $13.30 million. Recro Pharma posted sales of $17.36 million during the same quarter last year, which suggests a negative year-over-year growth rate of 23.3%. The firm is scheduled to announce its next earnings report on Monday, March 5th.

On average, analysts expect that Recro Pharma will report full year sales of $13.32 million for the current fiscal year, with estimates ranging from $62.50 million to $66.14 million. For the next financial year, analysts forecast that the company will report sales of $66.09 million per share, with estimates ranging from $63.60 million to $70.93 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that follow Recro Pharma.

Recro Pharma (NASDAQ:REPH) last posted its quarterly earnings data on Thursday, November 9th. The specialty pharmaceutical company reported ($0.48) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.75) by $0.27. Recro Pharma had a negative net margin of 51.88% and a negative return on equity of 60.01%.

Several research firms have recently weighed in on REPH. Zacks Investment Research cut shares of Recro Pharma from a “hold” rating to a “sell” rating in a research report on Wednesday, October 11th. Piper Jaffray Companies reiterated a “buy” rating and set a $11.00 price objective on shares of Recro Pharma in a research report on Friday, October 27th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $11.65.

In related news, major shareholder Scp Vitalife Partners (Israel) sold 12,964 shares of the stock in a transaction on Wednesday, January 3rd. The shares were sold at an average price of $8.88, for a total transaction of $115,120.32. Following the transaction, the insider now directly owns 734,269 shares of the company’s stock, valued at $6,520,308.72. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Healthcare Master Fun Broadfin sold 102,440 shares of the stock in a transaction on Tuesday, November 21st. The stock was sold at an average price of $9.50, for a total transaction of $973,180.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 860,414 shares of company stock worth $8,289,916. 21.60% of the stock is owned by insiders.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Schwab Charles Investment Management Inc. bought a new position in shares of Recro Pharma in the second quarter valued at $215,000. Bank of New York Mellon Corp lifted its stake in shares of Recro Pharma by 182.7% in the second quarter. Bank of New York Mellon Corp now owns 50,532 shares of the specialty pharmaceutical company’s stock valued at $355,000 after buying an additional 32,655 shares in the last quarter. Teachers Advisors LLC bought a new position in shares of Recro Pharma in the second quarter valued at $162,000. TIAA CREF Investment Management LLC bought a new position in shares of Recro Pharma in the second quarter valued at $249,000. Finally, Northern Trust Corp lifted its stake in shares of Recro Pharma by 428.5% in the second quarter. Northern Trust Corp now owns 178,437 shares of the specialty pharmaceutical company’s stock valued at $1,254,000 after buying an additional 144,676 shares in the last quarter. 61.55% of the stock is currently owned by institutional investors and hedge funds.

Shares of Recro Pharma (REPH) opened at $8.87 on Thursday. Recro Pharma has a 12-month low of $5.81 and a 12-month high of $10.59. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.35 and a current ratio of 1.59. The firm has a market cap of $169.63, a price-to-earnings ratio of -4.13 and a beta of -0.50.

TRADEMARK VIOLATION NOTICE: This piece was reported by American Banking News and is the property of of American Banking News. If you are reading this piece on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The original version of this piece can be viewed at https://www.americanbankingnews.com/2018/01/18/13-32-million-in-sales-expected-for-recro-pharma-inc-reph-this-quarter-2.html.

Recro Pharma Company Profile

Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.

Get a free copy of the Zacks research report on Recro Pharma (REPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.